{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:33:15Z","timestamp":1787236395954,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01401-4","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:13:33Z","timestamp":1783667613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current Treatment Options for Adult Grade 2 IDH-mutant Diffuse Gliomas in the Vorasidenib Era: Patient Selection, Sequencing, and Practical Management"],"prefix":"10.1007","volume":"27","author":[{"given":"Jianheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"8","key":"1401_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"issue":"4","key":"1401_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bpa.12832","volume":"30","author":"DN Louis","year":"2020","unstructured":"Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, Eberhart C, Figarella-Branger D, Fouladi M, Fuller GN, et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 2020;30(4):844\u201356.","journal-title":"Brain Pathol"},{"issue":"3","key":"1401_CR3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","volume":"139","author":"DJ Brat","year":"2020","unstructured":"Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C, Holland EC, Jenkins RB, Kleinschmidt-DeMasters B, Komori T, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020;139(3):603\u20138.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"1401_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023;389(7):589\u2013601.","journal-title":"N Engl J Med"},{"issue":"12","key":"1401_CR5","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S1470-2045(25)00472-3","volume":"26","author":"TF Cloughesy","year":"2025","unstructured":"Cloughesy TF, van den Bent MJ, Touat M, Blumenthal DT, Peters KB, Ellingson BM, Clarke JL, Mendez J, Yust-Katz S, Welsh L, et al. Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2025;26(12):1665\u201375.","journal-title":"Lancet Oncol"},{"issue":"21","key":"1401_CR6","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1158\/1078-0432.CCR-25-1333","volume":"31","author":"MI Barbato","year":"2025","unstructured":"Barbato MI, Barone AK, Aungst SL, Miller CP, Ananthula S, Bi Y, Yang Y, Li X, Xiong Y, Fan J, et al. FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery. Clin Cancer Res. 2025;31(21):4412\u20138.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1401_CR7","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1200\/JCO-25-00250","volume":"43","author":"J Blakeley","year":"2025","unstructured":"Blakeley J, Mohile NA, Messersmith H, Lassman AB, Schiff D, Therapy for Diffuse A. Oligodendroglial Tumors in Adults Guideline Expert P: Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update. J Clin Oncol. 2025;43(18):2129\u201333.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1401_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.21.02036","volume":"40","author":"NA Mohile","year":"2022","unstructured":"Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, et al. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. J Clin Oncol. 2022;40(4):403\u201326.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1401_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170\u201386.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"1401_CR10","first-page":"1519","volume":"21","author":"R Appay","year":"2019","unstructured":"Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 2019;21(12):1519\u201328.","journal-title":"Neuro Oncol"},{"issue":"8","key":"1401_CR11","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1200\/JCO.2002.08.121","volume":"20","author":"F Pignatti","year":"2002","unstructured":"Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20(8):2076\u201384.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1401_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3171\/2013.1.JNS121","volume":"118","author":"L Capelle","year":"2013","unstructured":"Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard JL, Bauchet L, Pallud J, Peruzzi P, Baron MH, Kujas M, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg. 2013;118(6):1157\u201368.","journal-title":"J Neurosurg"},{"issue":"12","key":"1401_CR13","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1093\/neuonc\/noaa105","volume":"22","author":"RY Huang","year":"2020","unstructured":"Huang RY, Young RJ, Ellingson BM, Veeraraghavan H, Wang W, Tixier F, Um H, Nawaz R, Luks T, Kim J, et al. Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro Oncol. 2020;22(12):1822\u201330.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1401_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.CCR-23-1180","volume":"30","author":"A Bhatia","year":"2024","unstructured":"Bhatia A, Moreno R, Reiner AS, Nandakumar S, Walch HS, Thomas TM, Nicklin PJ, Choi Y, Skakodub A, Malani R, et al. Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma. Clin Cancer Res. 2024;30(1):106\u201315.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1401_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejrad.2008.06.013","volume":"72","author":"J Rees","year":"2009","unstructured":"Rees J, Watt H, Jager HR, Benton C, Tozer D, Tofts P, Waldman A. Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol. 2009;72(1):54\u201364.","journal-title":"Eur J Radiol"},{"issue":"3","key":"1401_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/ana.20946","volume":"60","author":"J Pallud","year":"2006","unstructured":"Pallud J, Mandonnet E, Duffau H, Kujas M, Guillevin R, Galanaud D, Taillandier L, Capelle L. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol. 2006;60(3):380\u20133.","journal-title":"Ann Neurol"},{"issue":"5","key":"1401_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/neuonc\/nos331","volume":"15","author":"J Pallud","year":"2013","unstructured":"Pallud J, Blonski M, Mandonnet E, Audureau E, Fontaine D, Sanai N, Bauchet L, Peruzzi P, Frenay M, Colin P, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol. 2013;15(5):595\u2013606.","journal-title":"Neuro Oncol"},{"issue":"9490","key":"1401_CR18","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","volume":"366","author":"MJ van den Bent","year":"2005","unstructured":"van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985\u201390.","journal-title":"Lancet"},{"issue":"8","key":"1401_CR19","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1200\/JCO.2007.13.9337","volume":"26","author":"JS Smith","year":"2008","unstructured":"Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8):1338\u201345.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1401_CR20","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3171\/2011.7.JNS101238","volume":"115","author":"N Sanai","year":"2011","unstructured":"Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg. 2011;115(5):948\u201365.","journal-title":"J Neurosurg"},{"issue":"18","key":"1401_CR21","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1001\/jama.2012.12807","volume":"308","author":"AS Jakola","year":"2012","unstructured":"Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgard G, Solheim O. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012;308(18):1881\u20138.","journal-title":"JAMA"},{"issue":"8","key":"1401_CR22","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1093\/annonc\/mdx230","volume":"28","author":"AS Jakola","year":"2017","unstructured":"Jakola AS, Skjulsvik AJ, Myrmel KS, Sjavik K, Unsgard G, Torp SH, Aaberg K, Berg T, Dai HY, Johnsen K, et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017;28(8):1942\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"1401_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/neuonc\/nox176","volume":"20","author":"MMJ Wijnenga","year":"2018","unstructured":"Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Smits M, Gahrmann R, Rutten GJ, Verheul JB, et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol. 2018;20(1):103\u201312.","journal-title":"Neuro Oncol"},{"issue":"5","key":"1401_CR24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3171\/JNS\/2008\/109\/11\/0835","volume":"109","author":"EG Shaw","year":"2008","unstructured":"Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109(5):835\u201341.","journal-title":"J Neurosurg"},{"issue":"14","key":"1401_CR25","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","volume":"374","author":"JC Buckner","year":"2016","unstructured":"Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016;374(14):1344\u201355.","journal-title":"N Engl J Med"},{"issue":"25","key":"1401_CR26","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.2011.35.8598","volume":"30","author":"EG Shaw","year":"2012","unstructured":"Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012;30(25):3065\u201370.","journal-title":"J Clin Oncol"},{"issue":"29","key":"1401_CR27","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/JCO.19.02983","volume":"38","author":"EH Bell","year":"2020","unstructured":"Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, et al. Comprehensive Genomic Analysis in NRG Oncology\/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. J Clin Oncol. 2020;38(29):3407\u201317.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1401_CR28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0360-3016(96)00352-5","volume":"36","author":"AB Karim","year":"1996","unstructured":"Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36(3):549\u201356.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"1401_CR29","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/S1470-2045(16)30305-9","volume":"17","author":"JC Reijneveld","year":"2016","unstructured":"Reijneveld JC, Taphoorn MJB, Coens C, Bromberg JEC, Mason WP, Hoang-Xuan K, Ryan G, Hassel MB, Enting RH, Brandes AA, et al. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033\u201326033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1533\u201342.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1401_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/neuonc\/noaa252","volume":"23","author":"M Klein","year":"2021","unstructured":"Klein M, Drijver AJ, van den Bent MJ, Bromberg JC, Hoang-Xuan K, Taphoorn MJB, Reijneveld JC, Ben Hassel M, Vauleon E, Eekers DBP, et al. Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033\u201326033. Neuro Oncol. 2021;23(5):803\u201311.","journal-title":"Neuro Oncol"},{"issue":"9343","key":"1401_CR31","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/S0140-6736(02)11398-5","volume":"360","author":"M Klein","year":"2002","unstructured":"Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360(9343):1361\u20138.","journal-title":"Lancet"},{"issue":"9","key":"1401_CR32","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S1474-4422(09)70204-2","volume":"8","author":"L Douw","year":"2009","unstructured":"Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, Postma TJ, Vandertop WP, Mooij JJ, Boerman RH, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8(9):810\u20138.","journal-title":"Lancet Neurol"},{"issue":"13","key":"1401_CR33","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1200\/JCO.2003.04.172","volume":"21","author":"PD Brown","year":"2003","unstructured":"Brown PD, Buckner JC, O\u2019Fallon JR, Iturria NL, Brown CA, O\u2019Neill BP, Scheithauer BW, Dinapoli RP, Arusell RM, Curran WJ, et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol. 2003;21(13):2519\u201324.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1401_CR34","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","volume":"17","author":"BG Baumert","year":"2016","unstructured":"Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033\u201326033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1521\u201332.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1401_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1200\/JCO.2013.53.1830","volume":"32","author":"RS Prabhu","year":"2014","unstructured":"Prabhu RS, Won M, Shaw EG, Hu C, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98\u2009\u2013\u200902. J Clin Oncol. 2014;32(6):535\u201341.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1401_CR36","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2017.12.258","volume":"100","author":"ES Murphy","year":"2018","unstructured":"Murphy ES, Leyrer CM, Parsons M, Suh JH, Chao ST, Yu JS, Kotecha R, Jia X, Peereboom DM, Prayson RA, et al. Risk Factors for Malignant Transformation of Low-Grade Glioma. Int J Radiat Oncol Biol Phys. 2018;100(4):965\u201371.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1401_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3171\/2008.10.JNS08608","volume":"112","author":"KL Chaichana","year":"2010","unstructured":"Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quinones-Hinojosa A. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg. 2010;112(1):10\u20137.","journal-title":"J Neurosurg"},{"issue":"8","key":"1401_CR38","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765\u201373.","journal-title":"N Engl J Med"},{"issue":"7274","key":"1401_CR39","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739\u201344.","journal-title":"Nature"},{"issue":"7390","key":"1401_CR40","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature10866","volume":"483","author":"S Turcan","year":"2012","unstructured":"Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479\u201383.","journal-title":"Nature"},{"issue":"29","key":"1401_CR41","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1200\/JCO.19.03327","volume":"38","author":"IK Mellinghoff","year":"2020","unstructured":"Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, Cote GM, Burris H, Janku F, Young RJ, et al. Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. J Clin Oncol. 2020;38(29):3398\u2013406.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1401_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","volume":"11","author":"Z Konteatis","year":"2020","unstructured":"Konteatis Z, Artin E, Nicolay B, Straley K, Padyana AK, Jin L, Chen Y, Narayaraswamy R, Tong S, Wang F, et al. Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. ACS Med Chem Lett. 2020;11(2):101\u20137.","journal-title":"ACS Med Chem Lett"},{"issue":"16","key":"1401_CR43","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-21-0611","volume":"27","author":"IK Mellinghoff","year":"2021","unstructured":"Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA 3rd, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM, et al. Vorasidenib, a Dual Inhibitor of Mutant IDH1\/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clin Cancer Res. 2021;27(16):4491\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1401_CR44","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","volume":"29","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, et al. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2023;29(3):615\u201322.","journal-title":"Nat Med"},{"issue":"33","key":"1401_CR45","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, Galanis E, Barboriak DP, de Groot J, Gilbert MR, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol. 2023;41(33):5187\u201399.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1401_CR46","first-page":"1188","volume":"17","author":"BM Ellingson","year":"2015","unstructured":"Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015;17(9):1188\u201398.","journal-title":"Neuro Oncol"},{"issue":"6","key":"1401_CR47","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1470-2045(11)70057-2","volume":"12","author":"MJ van den Bent","year":"2011","unstructured":"van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12(6):583\u201393.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1401_CR48","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3171\/2016.12.JNS161682","volume":"128","author":"DS Xu","year":"2018","unstructured":"Xu DS, Awad AW, Mehalechko C, Wilson JR, Ashby LS, Coons SW, Sanai N. An extent of resection threshold for seizure freedom in patients with low-grade gliomas. J Neurosurg. 2018;128(4):1084\u201390.","journal-title":"J Neurosurg"},{"issue":"2","key":"1401_CR49","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/cancers12020397","volume":"12","author":"T Ius","year":"2020","unstructured":"Ius T, Pauletto G, Tomasino B, Maieron M, Budai R, Isola M, Cesselli D, Lettieri C, Skrap M. Predictors of Postoperative Seizure Outcome in Low Grade Glioma: From Volumetric Analysis to Molecular Stratification. Cancers (Basel). 2020;12(2):397.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1401_CR50","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11060-022-04158-6","volume":"160","author":"L Carstam","year":"2022","unstructured":"Carstam L, Ryden I, Jakola AS. Seizures in patients with IDH-mutated lower grade gliomas. J Neurooncol. 2022;160(2):403\u201311.","journal-title":"J Neurooncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01401-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01401-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01401-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T08:01:52Z","timestamp":1783670512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01401-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1401"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01401-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}